MorphoSys AG (NASDAQ:MOR) Given Consensus Rating of “Hold” by Analysts

MorphoSys AG (NASDAQ:MOR) has been given an average rating of “Hold” by the eight analysts that are covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $11.78.

A number of research analysts recently weighed in on the stock. Wells Fargo & Company reissued an “equal weight” rating and issued a $18.25 target price (up from $17.00) on shares of MorphoSys in a report on Thursday, March 14th. Morgan Stanley reiterated an “equal weight” rating on shares of MorphoSys in a research note on Friday, January 19th.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Quadrant Capital Group LLC raised its stake in MorphoSys by 204.8% in the 4th quarter. Quadrant Capital Group LLC now owns 5,572 shares of the company’s stock valued at $55,000 after purchasing an additional 3,744 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in MorphoSys by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 17,437 shares of the company’s stock worth $173,000 after acquiring an additional 4,421 shares in the last quarter. Virtu Financial LLC acquired a new stake in MorphoSys in the 4th quarter valued at about $244,000. Henry James International Management Inc. acquired a new stake in MorphoSys in the 4th quarter valued at about $426,000. Finally, Hennion & Walsh Asset Management Inc. raised its position in shares of MorphoSys by 71.4% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 116,901 shares of the company’s stock worth $2,121,000 after acquiring an additional 48,710 shares in the last quarter. 18.38% of the stock is owned by institutional investors and hedge funds.

MorphoSys Price Performance

MOR opened at $18.05 on Friday. The company has a debt-to-equity ratio of 4.98, a quick ratio of 2.84 and a current ratio of 3.08. The stock has a market capitalization of $2.72 billion, a P/E ratio of -11.57 and a beta of 1.17. The company’s 50-day simple moving average is $17.93 and its two-hundred day simple moving average is $12.07. MorphoSys has a 52-week low of $4.18 and a 52-week high of $18.31.

MorphoSys (NASDAQ:MOR) last issued its quarterly earnings data on Wednesday, March 13th. The company reported $0.33 earnings per share for the quarter, topping the consensus estimate of ($0.92) by $1.25. MorphoSys had a negative net margin of 80.07% and a negative return on equity of 694.31%. The firm had revenue of $63.53 million for the quarter, compared to analysts’ expectations of $76.30 million. As a group, analysts predict that MorphoSys will post -2.08 EPS for the current year.

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity.